Alzheimer's disease (AD) is the most common progressive dementing disease in elder population. According to the World Health Organization, there are estimated 34 millions of people with Alzheimer's disease worldwide. More then a decade after the first approval of donezepil, we still do not have a single treatment that can effectively stop the relentless progression of disease or can help prevent the disease. Several failures in disease-modifying therapies in phase III clinical trials led to debates about our understanding of the pathogenesis of AD. Until now, there are four acetylcholine esterase inhibitors and one NDMA antagonist under the approval of FDA. Many experimental and clinical studies are ongoing, based on targeting the pathogenesis of AD which should be composed of multi-factors and those closely related. These include gamma secretase inhibitors for reducing beta amyloid formation, immunotherapies for enhancing clearance of the amyloid plaques, therapies targeting hyperphosphorylated tau protein, microtubules stabilizing drugs, antioxidant agents, and others such like insulin are also tackled with. A single cure for Alzheimer's disease is unlikely to be found. Thus, the need to better understand the pathogenesis of AD is warranted. This article presents current practice and future developments of treatment for AD.